Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.20501 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Methotrexate for atopic dermatitis: The right dosing and best-performance administration route.
J Eur Acad Dermatol Venereol
February 2025
CIRI (International Center for Infectiology Research) INSERM U1111, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1 CNRS UMR5308, Lyon, France.
The cardiometabolic safety of dupilumab in atopic dermatitis: A global large-scale cohort study.
Arch Dermatol Res
January 2025
Lűbeck Institute of Experimental Dermatology, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.
Background: A low risk of cardiovascular and metabolic outcomes was found in the randomized clinical trials of dupilumab in atopic dermatitis (AD). Dupilumab-associated real-life long-term cardiometabolic risk relative to other systemic agents is yet to be precisely investigated.
Objective: To assess the risk of cardiometabolic outcomes in patients with AD treated with dupilumab relative to those treated with methotrexate and cyclosporine.
Dupilumab and neuropsychiatric outcomes in pediatric atopic dermatitis: a real-world cohort analysis.
J Am Acad Dermatol
January 2025
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address:
Live Attenuated Vaccine Administration in Children Treated With Methotrexate or Dupilumab.
Pediatr Dermatol
December 2024
Department of Pediatrics and Dermatology, SSM Health and Saint Louis University, St. Louis, Missouri, USA.
Background And Objectives: A wholesale recommendation against use of live virus vaccines in patients treated with any medication classified as an immunosuppressant has been based on global theoretical concerns rather than clinical outcomes for specific drugs.
Methods: A retrospective search of electronic medical records identified patients seen by the Allergy and/or Dermatology services between 2017 and 2023 at a pediatric tertiary center who received a live attenuated vaccine during the 6 week interval prior to the first prescription for methotrexate or dupilumab until 6 weeks after the last prescription for either medication. Individual charts of identified patients were manually reviewed for evidence of adverse events.
Dupilumab impact on psychiatric and sleep disorder risk reduction in atopic dermatitis: A population-based cohort study.
Ann Allergy Asthma Immunol
November 2024
Faculty of Medicine and Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei, Taiwan; Division of Translational Research, Taipei Veterans General Hospital, Taipei, Taiwan; College of Public Health, China Medical University, Taichung, Taiwan.
Article Synopsis
- - Patients with atopic dermatitis (AD) are at higher risk for psychiatric and sleep disorders, prompting a study to compare the risks between those treated with dupilumab and conventional drugs.
- - The study analyzed 12,228 adult patients, showing that those on dupilumab had significantly lower risks of anxiety, depressive disorders, adjustment disorders, and sleep disorders compared to those on conventional treatments, though ADHD risk remained unchanged.
- - Findings suggest that dupilumab may be particularly beneficial for reducing psychiatric and sleep disorder risks in AD patients, especially among Black or African American individuals.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!